September 8, 2017 10:29 AM EDT
News Briefing

Ku­ra shares soar on pos­i­tive PhII can­cer da­ta; M&A buzz re­volves back to As­traZeneca

Shehla Shakoor

Managing Director

⇨ In­vestors are in an en­thu­si­as­tic mood when it comes to any­thing that looks pos­i­tive on the can­cer drug de­vel­op­ment side of things. To­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times